DataHarmony Revenue

About DataHarmony

We support academic research and clinical developments in gene editing and gene therapy across Europe. Our AI gene editing cockpit consolidates everything in one place by merging AI-driven genome editor selection and design with a directory linking third-party vendors of essential reagents and DNA sequencing providers, alongside scalable analysis of gene editing outcomes. Our platform offers expert guidance, integrations, and automation to assist researchers in designing, analysing, and reporting their R&D. This significantly reduces experimental timelines, enhances the validity of research, and fosters more efficient experiment replication, ultimately mitigating risks in future clinical trials that depend on this early-stage academic research. We aim to enhance the quality and speed of gene editing and gene therapy research. Users can detail what genetic mutation they want to make, and our platform suggests an ideal experiment protocol, what consumables should be ordered, and how to track each step of the experiment. Users are then prompted to use specific third party workflows, or generate novel outputs, in an intuitive and friendly manner. We are currently looking for funding for our pre-seed round, which is anticipated to close in Q3 of this year. If you are interested in investing, we'd love to hear from you. If you are a researcher in the gene editing or gene therapy space, and would like to trial our platform, please get in touch and we'd be happy to have a conversation.

View contact profiles from DataHarmony